Table 2.
Pharmacological Activities of Bromophycolides R–U (1–4)
| antimalarial activity |
antibacterial activity (μM) |
antifungal activitya |
anticancer activity (μM) |
||||
|---|---|---|---|---|---|---|---|
| cmpd | IC50 (μM) | MRSA IC50 | VREF IC50 |
M. tuberculosis MIC |
IC50 (μM) | meanb | cell line selectivity (IC50 max/IC50 min) |
| 1 | 1.7 | >15 | >15 | >50 | >15 | 19 | 2.9 |
| 2 | 0.9 | >15 | 3.8 | 23 | >15 | 16 | 2.2 |
| 3 | 8.4 | >15 | >15 | >50 | >15 | 24 | 1.6 |
| 4 | 2.1 | 0.9 | 0.9 | 22 | >15 | 16 3 | 1 |
a
Using amphotericin-resistant Candida albicans.
b
Mean of 12 cancer cell lines (see the Experimental Section for details). MRSA = methicillin-resistant Staphylococcus aureus; VREF = vancomycin-resistant Enterococcus faecium.